Evidence map›Paper›PMID 40247352›Full record

ArticleArthritis research & therapy2025

Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study.

Teppei Hashimoto, Kazuyuki Tsuboi, Takeo Abe, Takahiro Yoshikawa, Kazuteru Noguchi, Tetsuya Furukawa, Koji Tateishi, Yasuhiro Terashima, Nao Sibanuma, Naoto Azuma and 3 more

Abstract readControlled Clinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Teppei HashimotoDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Kazuyuki TsuboiDepartment of Rheumatology, Kobe City Medical Center West Hospital, Kobe, Japan.
Takeo AbeDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Takahiro YoshikawaDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Kazuteru NoguchiDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Tetsuya FurukawaDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Koji TateishiDepartment of Orthopedics, Hakuhokai Kakogawa Hospital, Kakogawa, Japan.
Yasuhiro TerashimaDepartment of Orthopedics, Hakuhokai Kakogawa Hospital, Kakogawa, Japan.
Nao SibanumaDepartment of Orthopedics, Kobe Kaisei Hospital, Kobe, Japan.
Naoto AzumaDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Takashi YamaneDepartment of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Japan.
Kiyoshi MatsuiDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Akira HashiramotoDepartment of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan. hash@med.kobe-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory cytokine levels exhibit a circadian rhythm in sera, peaking from late night to early morning in patients with rheumatoid arthritis (RA). This cytokine kinetics is a recognized therapeutic target. This clinical study aimed to evaluate the effectiveness of night-time baricitinib administration based on cytokine secretion.

methodsIn this 52-week multicenter non-randomized controlled study, 122 patients with RA were assigned to four groups: baricitinib 2 mg morning (BAR2MORN), 2 mg evening (BAR2EVE), 4 mg morning (BAR4MORN), or 4 mg evening (BAR4EVE). The primary endpoint was assessed using the 20% improvement in the American College of Rheumatology criteria (ACR20) at week 12. The secondary endpoints were ACR20/50/70 and changes in the clinical disease activity index (CDAI) through 52 weeks. The results were evaluated using the propensity score inverse probability of treatment weighted to reduce selection bias in patient background.

resultsBAR4EVE resulted in better primary endpoint improvement than BAR4MORN (78.2 vs. 43.3%; p < 0.001). No difference in improvement was observed in the primary endpoint between BAR2EVE and BAR2MORN (75.5 vs. 60.6%; p = 0.10). However, BAR2EVE demonstrated higher ACR20 at weeks 4, 24, and 52 and ACR50 at weeks 4 and 12 than BAR2MORN. BAR4EVE demonstrated higher ACR20/50 at weeks 4, 8, and 12 and ACR70 at weeks 8, 12, and 24 than BAR4MORN. CDAI changes were significantly reduced in BAR4EVE than in BAR4MORN at weeks 4 and 8.

conclusionChronotherapy targeting cytokine secretion resulted in rapid drug response, proposing a new potential application for JAK inhibitors.

trial registrationUMIN000040094, July 1, 2020.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAzetidinesCircadian RhythmPyrazolesSulfonamidesAdultAgedCytokinesFemaleHumansMaleMiddle AgedPurinesTreatment OutcomeAntirheumatic AgentsAzetidinesbaricitinibCytokinesPurinesPyrazolesSulfonamidesBaricitinibChronotherapyJAK inhibitorRheumatoid arthritis

Identifiers

PMID40247352
PMCPMC12004773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.